Vitasora Health Limited · ASX:VHL
Vitasora Health — Investor Presentation (March 2021)
11 slides from Vitasora Health's investor presentation, Mar 23, 2021
Slide 1: Respiri: A Respiratory eHealth MedTech Company
RESPIRI: A Respiratory eHealth MedTech Company Extending Care Beyond the Clinic 23rd March 2021 1 Marjan Mikel (RESPIRI CEO)
Slide 2: Our Mission and Vision
OUR MISSION To improve asthma management by extending care beyond the clinic OUR VISION A world without the challenges of asthma 2
Slide 3: Meet wheezo
Wheeze Detection The device records breath sounds over 30 seconds to be analysed in the app for the presence of wheeze Continuous Monitoring App allows users to also log symptoms, triggers, medication and local environmental factors Asthma Action Plan meet wheezo Wheezo allows for the digitisation o
Slide 4: OTC Class II FDA Approval for wheezo
OTC CLASS II FDA APPROVAL FOR wheezo This allows Respiri to target more channels in the USA including • Class II Medical Device opening up reimbursement possibilities • CPT Reimbursement Codes for Remote Patient Monitoring (RPM) physician prescription • Pharmacy/Retail channels without prescription
Slide 5: USA Market Opportunity
COPD: Chronic obstructive pulmonary disease USA MARKET OPPORTUNITY 3.3 million children with persistent and severe asthma and total 12.5 million target patient population 9.8 million Physician visits p.a. 1.6 million emergency department visits p.a. 3.3 million children with persistent and severe as
Slide 6: Pharmacy Opportunity
PHARMACY OPPORTUNITY - 88,000+ pharmacies in the USA - ~22,000 are independent - ~66,000 are large chains - Worth USD319B pa and growing at 3.3% - ~30% through online sales - Major players Walmart, Walgreens, Costco Cipla current partner in Australia and have 1st right of refusal for other markets.
Slide 7: Reimbursement Opportunity
REIMBURSEMENT OPPORTUNITY OPPORTUNITY OPPORTUNITY A US patient generates up to 5 x the annual revenue of an Australian patient. 2021 Payment Little or no out of pocket expense to patient unlike Australia Rates 1 2 3 Provider sets p a ti e n t u p on a Physiological data Data sent in real time & remo
Slide 8: Strategy: Existing Channels
STRATEGY Current discussions will open up the professional disease management market via immediate distribution capabilities into specialist clinics & disease management providers, whilst Cipla provide a distribution option in pharmacy Right time Channel Planned Revenue Model Partner Monthly recurri
Slide 9: Commercialisation Timelines and Milestones
COMMERCIALISATION TIMELINES Q2 CY2022 Pre and Interim Launch Insights Q1 CY2022 Insight Building ▪ Partners trained ▪ Promote wheezo to CMO/HMO and ensure CPT Q3 CY2021 Codes are covered. Ready for Milestones Build the foundations for ▪ Stock pharmacy and wheezo Disease Management Launch ▪ Key Hires
Slide 10: Thank You, Questions?
THANK YOU QUESTIONS? MARJAN MIKEL, CEO MARJAN@RESPIRI.CO +61 408 462 873 1 0
Slide 11: Forward Looking Statements
FORWARD LOOKING STATEMENTS Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on Respiri’s current expectations, estimates and projections about the industry in which Respiri operates, and its be